Information Provided By:
Fly News Breaks for November 6, 2019
Nov 6, 2019 | 05:57 EDT
Canaccord analyst John Newman initiated coverage of Global Blood Therapeutics with a Hold rating and $50 price target.
News For GBT From the Last 2 Days
Dec 13, 2019 | 09:45 EST
Biotech Analyst Young, along with Key Opinion Leader Dr. Vivien Sheehan, Asst Professor in Pediatrics-Hematology at Baylor College of Medicine, discuss the near-term and long-term uptake of Global Blood Therapeutics' Oxbryta, Adakvea (P-selectin antibody by Novartis) and Teva/Bristol-Myers Hydroxyurea in Sickle Cell Disease on an Analyst/Industry conference call to be held on December 17 at 1 pm.